Literature DB >> 29723785

Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands.

Katarzyna Szczepańska1, Tadeusz Karcz1, Szczepan Mogilski2, Agata Siwek3, Kamil J Kuder1, Gniewomir Latacz1, Monika Kubacka2, Stefanie Hagenow4, Annamaria Lubelska1, Agnieszka Olejarz1, Magdalena Kotańska2, Bassem Sadek5, Holger Stark4, Katarzyna Kieć-Kononowicz6.   

Abstract

As a continuation of our search for novel histamine H3 receptor ligands, a series of twenty four new tert-butyl and tert-pentyl phenoxyalkylamine derivatives (2-25) was synthesized. Compounds with three to four carbon atoms alkyl chain spacer were evaluated for their binding properties at human histamine H3 receptor (hH3R). The highest affinities were observed for 4-pyridyl derivatives 4, 10, 16 and 22 (Ki = 16.0-120 nM). As it has been shown in docking studies, those specific heteroaromatic 4-N piperazine substituents might interact with one of the key receptor interacting amino acids. Moreover, the most promising compounds exhibited anticonvulsant activity in the maximal electroshock-induced seizure (MES) model in mice. Furthermore, the blood-brain barrier penetration, the functional H3R antagonist potency as well as the pro-cognitive properties in the passive avoidance test were demonstrated for compound 10. In order to estimate drug-likeness of compound 10,in silico and experimental evaluation of metabolic stability in human liver microsomes was performed. In addition, paying attention to the results obtained within this study, the 4-pyridyl-piperazino moiety has been established as a new bioisosteric piperidine replacement in H3R ligands.
Copyright © 2018. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Anticonvulsants; Histamine H(3) receptor; Histamine H(3) receptor ligands; Metabolic stability; Molecular docking; Non-imidazole histamine H(3)R ligands; Piperazine derivatives; Pro-cognitives

Mesh:

Substances:

Year:  2018        PMID: 29723785     DOI: 10.1016/j.ejmech.2018.04.043

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Chemical Probes for Histamine Receptor Subtypes.

Authors:  Markus Falkenstein; Milica Elek; Holger Stark
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Simplified Procedure for General Synthesis of Monosubstituted Piperazines-From a Batch Reaction Vessel to a Flow (Microwave) Reactor.

Authors:  Dana Němečková; Eva Havránková; Jan Šimbera; Richard Ševčík; Pavel Pazdera
Journal:  Molecules       Date:  2020-05-06       Impact factor: 4.411

3.  Design, synthesis, and anticonvulsant effects evaluation of nonimidazole histamine H3 receptor antagonists/inverse agonists containing triazole moiety.

Authors:  Mingxia Song; Rui Yan; Yanhui Zhang; Dongfu Guo; Naiming Zhou; XianQing Deng
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

4.  Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties.

Authors:  Kamil J Kuder; Magdalena Kotańska; Katarzyna Szczepańska; Kamil Mika; David Reiner-Link; Holger Stark; Katarzyna Kieć-Kononowicz
Journal:  Molecules       Date:  2021-04-15       Impact factor: 4.411

5.  Structural and Molecular Insight into Piperazine and Piperidine Derivatives as Histamine H3 and Sigma-1 Receptor Antagonists with Promising Antinociceptive Properties.

Authors:  Katarzyna Szczepańska; Sabina Podlewska; Maria Dichiara; Davide Gentile; Vincenzo Patamia; Niklas Rosier; Denise Mönnich; Ma Carmen Ruiz Cantero; Tadeusz Karcz; Dorota Łażewska; Agata Siwek; Steffen Pockes; Enrique J Cobos; Agostino Marrazzo; Holger Stark; Antonio Rescifina; Andrzej J Bojarski; Emanuele Amata; Katarzyna Kieć-Kononowicz
Journal:  ACS Chem Neurosci       Date:  2021-12-15       Impact factor: 4.418

Review 6.  Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.

Authors:  Paweł Kozyra; Monika Pitucha
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.